BR112019003951A2 - métodos e composição para a predição da atividade de enzastaurina - Google Patents
métodos e composição para a predição da atividade de enzastaurinaInfo
- Publication number
- BR112019003951A2 BR112019003951A2 BR112019003951A BR112019003951A BR112019003951A2 BR 112019003951 A2 BR112019003951 A2 BR 112019003951A2 BR 112019003951 A BR112019003951 A BR 112019003951A BR 112019003951 A BR112019003951 A BR 112019003951A BR 112019003951 A2 BR112019003951 A2 BR 112019003951A2
- Authority
- BR
- Brazil
- Prior art keywords
- enzastaurin
- prediction
- activity
- composition
- methods
- Prior art date
Links
- AXRCEOKUDYDWLF-UHFFFAOYSA-N 3-(1-methyl-3-indolyl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-3-indolyl]pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 229950002189 enzastaurin Drugs 0.000 title abstract 2
- 239000000090 biomarker Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382734P | 2016-09-01 | 2016-09-01 | |
| US201662414601P | 2016-10-28 | 2016-10-28 | |
| PCT/US2017/049747 WO2018045240A1 (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019003951A2 true BR112019003951A2 (pt) | 2019-06-25 |
Family
ID=59923555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019003951A BR112019003951A2 (pt) | 2016-09-01 | 2017-08-31 | métodos e composição para a predição da atividade de enzastaurina |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11421280B2 (https=) |
| EP (1) | EP3507384B1 (https=) |
| JP (3) | JP7197915B2 (https=) |
| KR (1) | KR20190046935A (https=) |
| CN (1) | CN109952383B (https=) |
| AU (1) | AU2017318669B2 (https=) |
| BR (1) | BR112019003951A2 (https=) |
| CA (1) | CA3035386A1 (https=) |
| JO (1) | JOP20190025A1 (https=) |
| MX (1) | MX2019002377A (https=) |
| PH (1) | PH12019500422A1 (https=) |
| RU (1) | RU2019109011A (https=) |
| SG (2) | SG11201901762WA (https=) |
| TW (2) | TWI771317B (https=) |
| WO (1) | WO2018045240A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
| CN110496223B (zh) * | 2018-05-17 | 2021-09-10 | 复旦大学附属肿瘤医院 | 一种治疗非霍奇金氏淋巴瘤的药物组合物 |
| CN112512527A (zh) * | 2018-09-12 | 2021-03-16 | 杭州索元生物医药股份有限公司 | 恩扎妥林和btk抑制剂的组合及其用途 |
| CN111549033B (zh) * | 2020-06-11 | 2021-02-12 | 南京市江宁医院 | 慢病毒感染人表皮角质细胞株及其构建方法和应用 |
| US11227690B1 (en) * | 2020-09-14 | 2022-01-18 | Opendna Ltd. | Machine learning prediction of therapy response |
| WO2023001178A1 (zh) * | 2021-07-23 | 2023-01-26 | 高雄医学大学 | 用于评估二代荷尔蒙药物治疗前列腺癌疗效的临床治疗药物预测和推荐系统及方法 |
| US20230131677A1 (en) * | 2021-10-21 | 2023-04-27 | Toyota Research Institute, Inc. | Systems and methods for predicting the effect of an intervention via machine learning |
| CN118339312A (zh) * | 2021-11-23 | 2024-07-12 | 索元生物医药(美国)有限公司 | 用于评估多核苷酸递送和癌疗法之功效的组合物和方法 |
| US12474842B2 (en) * | 2021-12-13 | 2025-11-18 | Google Llc | Optimizing data placement based on data temperature and lifetime prediction |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2236702T3 (es) | 1993-12-23 | 2005-07-16 | Eli Lilly And Company | Inhibidores de la proteina quinasa c. |
| AU2001285047A1 (en) * | 2000-08-16 | 2002-02-25 | Chiron Corporation | Human genes and gene expression products |
| US20040072217A1 (en) | 2002-06-17 | 2004-04-15 | Affymetrix, Inc. | Methods of analysis of linkage disequilibrium |
| CA2393720C (en) | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| WO2007145992A2 (en) | 2006-06-05 | 2007-12-21 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| AU2012212499A1 (en) | 2011-01-31 | 2013-08-22 | Denovo Biomarkers Inc. | Method for discovering pharmacogenomic biomarkers |
| KR20140039278A (ko) | 2011-06-08 | 2014-04-01 | 드노보 바이오파마 (항주) 리미티드 코포레이션 | 레티노이드 x 수용체 모듈레이터 활성 예측 방법 및 조성물 |
| JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
-
2017
- 2017-06-16 JO JOP/2019/0025A patent/JOP20190025A1/ar unknown
- 2017-08-31 JP JP2019512609A patent/JP7197915B2/ja active Active
- 2017-08-31 EP EP17771623.0A patent/EP3507384B1/en active Active
- 2017-08-31 TW TW106129838A patent/TWI771317B/zh not_active IP Right Cessation
- 2017-08-31 CA CA3035386A patent/CA3035386A1/en active Pending
- 2017-08-31 CN CN201780066737.5A patent/CN109952383B/zh active Active
- 2017-08-31 US US16/327,788 patent/US11421280B2/en active Active
- 2017-08-31 SG SG11201901762WA patent/SG11201901762WA/en unknown
- 2017-08-31 AU AU2017318669A patent/AU2017318669B2/en not_active Ceased
- 2017-08-31 BR BR112019003951A patent/BR112019003951A2/pt not_active IP Right Cessation
- 2017-08-31 KR KR1020197009407A patent/KR20190046935A/ko not_active Ceased
- 2017-08-31 WO PCT/US2017/049747 patent/WO2018045240A1/en not_active Ceased
- 2017-08-31 MX MX2019002377A patent/MX2019002377A/es unknown
- 2017-08-31 TW TW111122709A patent/TW202313973A/zh unknown
- 2017-08-31 RU RU2019109011A patent/RU2019109011A/ru unknown
- 2017-08-31 SG SG10201912134TA patent/SG10201912134TA/en unknown
-
2019
- 2019-02-27 PH PH12019500422A patent/PH12019500422A1/en unknown
-
2020
- 2020-08-26 JP JP2020142358A patent/JP2020188816A/ja active Pending
-
2022
- 2022-08-18 US US17/820,772 patent/US20230074781A1/en not_active Abandoned
- 2022-09-16 JP JP2022148064A patent/JP2022173308A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201901762WA (en) | 2019-03-28 |
| AU2017318669A1 (en) | 2019-03-07 |
| WO2018045240A1 (en) | 2018-03-08 |
| US11421280B2 (en) | 2022-08-23 |
| JP2020188816A (ja) | 2020-11-26 |
| CA3035386A1 (en) | 2018-03-08 |
| MX2019002377A (es) | 2019-09-05 |
| JP2022173308A (ja) | 2022-11-18 |
| TW202313973A (zh) | 2023-04-01 |
| PH12019500422A1 (en) | 2019-05-27 |
| AU2017318669B2 (en) | 2023-04-20 |
| JOP20190025A1 (ar) | 2019-02-19 |
| TW201812125A (zh) | 2018-04-01 |
| EP3507384A1 (en) | 2019-07-10 |
| KR20190046935A (ko) | 2019-05-07 |
| CN109952383B (zh) | 2024-01-05 |
| JP7197915B2 (ja) | 2022-12-28 |
| SG10201912134TA (en) | 2020-02-27 |
| US20230074781A1 (en) | 2023-03-09 |
| US20190233902A1 (en) | 2019-08-01 |
| EP3507384B1 (en) | 2023-08-30 |
| JP2019528705A (ja) | 2019-10-17 |
| RU2019109011A (ru) | 2020-10-05 |
| TWI771317B (zh) | 2022-07-21 |
| RU2019109011A3 (https=) | 2021-01-22 |
| CN109952383A (zh) | 2019-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019003951A2 (pt) | métodos e composição para a predição da atividade de enzastaurina | |
| CL2019002427A1 (es) | Inhibición de smarca2 para el tratamiento de cáncer. | |
| CO2020002588A2 (es) | Composiciones que comprenden un inhibidor de shp2 y metodos para tratar el cáncer | |
| BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
| BR112019010646A2 (pt) | métodos de tratamento de condições inflamatórias | |
| EA201992131A1 (ru) | Высокоаффинные специфичные к mage-a1 tcr и их применение | |
| BR112016025048A2 (pt) | compostos e composições como agonistas do receptor tipo toll7 | |
| MX2018012492A (es) | Métodos para monitorear y tratar el cáncer. | |
| BR112018013853A2 (pt) | composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações de câncer | |
| EA201500835A1 (ru) | Терапевтическая и диагностическая мишень для рака, включающая dll3-связывающие реагенты | |
| SG195191A1 (en) | Methods and compositions of predicting activity of retinoid x receptor modulator | |
| BR112017008045A2 (pt) | compostos como inibidores de nik | |
| BR112017007975A2 (pt) | composições e métodos para o tratamento de disfunção das glândulas meibomianas | |
| BR112016004305A2 (pt) | métodos diagnósticos e composições para tratamento de glioblastoma | |
| BR112019005328A2 (pt) | composição farmacêutica líquida | |
| MX2017010919A (es) | Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias. | |
| BR112018071583A2 (pt) | métodos para determinar dpp3 e métodos terapêuticos | |
| MX391815B (es) | AGENTES DE iARN, COMPOSICIONES Y METODOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON TRANSTITERINA (TTR). | |
| MX2018012493A (es) | Métodos para controlar y tratar el cáncer. | |
| CO2020008863A2 (es) | Biomarcadores de tolerancia inmunitaria inducida por metotrexato | |
| CR20180199A (es) | Acetamida tienotriazolodiazepinas y usos de las mismas | |
| BR112015017241A2 (pt) | doadores de nitroxil com índice terapêutico melhorado | |
| BR112016001781A2 (pt) | inibidores de rorc2 e métodos de uso dos mesmos | |
| BR112017007715A2 (pt) | derivados de tienopirimidina como inibidores de nik | |
| BR112018069930A2 (pt) | agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2738 DE 27-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |